Deep Genomics discovers genetic disorder treatment drug via AI BetaKit

Deep Genomics, the Toronto-based AI therapeutics startup, has made the first-ever discovery of a diseases treatment and drug candidate using artificial intelligence. The startup announced on Wednesday that its propriety AI-based drug discovery platform has identified a novel treatment target and corresponding drug candidate for Wilson disease, a rare and potentially life-threatening genetic disorder. "Our AI systems can figure out how diseases are caused and how to fix those diseases much more rapidly than humans ever could." "This is the amazing accomplishment for the team," Brendan Frey, founder and CEO of Deep Genomics, told BetaKit. He noted that part of Deep Genomic's goal is to "help everyone in the world" use the discovery and technology its developing in Canada to support discovery and development more broadly.